17.97
price up icon1.87%   0.33
pre-market  Pre-mercato:  17.90   -0.07   -0.39%
loading
Precedente Chiudi:
$17.64
Aprire:
$17.52
Volume 24 ore:
2.07M
Relative Volume:
1.21
Capitalizzazione di mercato:
$1.60B
Reddito:
$217.42M
Utile/perdita netta:
$-243.25M
Rapporto P/E:
-6.4289
EPS:
-2.7952
Flusso di cassa netto:
$-278.35M
1 W Prestazione:
+1.64%
1M Prestazione:
-8.18%
6M Prestazione:
-25.19%
1 anno Prestazione:
+19.72%
Intervallo 1D:
Value
$17.18
$18.11
Intervallo di 1 settimana:
Value
$17.09
$18.56
Portata 52W:
Value
$12.99
$25.59

Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile

Name
Nome
Syndax Pharmaceuticals Inc
Name
Telefono
781-419-1400
Name
Indirizzo
730 THIRD AVENUE, NEW YORK, MA
Name
Dipendente
298
Name
Cinguettio
@syndax
Name
Prossima data di guadagno
2026-11-02
Name
Ultimi documenti SEC
Name
SNDX's Discussions on Twitter

Compare SNDX vs VRTX, REGN, MRNA, ARGX, RVMD

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
SNDX icon
SNDX
Syndax Pharmaceuticals Inc
17.97 1.60B 217.42M -243.25M -278.35M -2.7952
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
522.38 132.40B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
796.02 81.95B 14.92B 4.42B 3.79B 41.04
MRNA icon
MRNA
Moderna Inc
194.82 77.78B 2.23B -3.19B -1.60B -8.1462
ARGX icon
ARGX
Argen X Se Adr
962.22 60.20B 4.16B 1.29B 734.26M 19.58
RVMD icon
RVMD
Revolution Medicines Inc
199.86 42.84B 742.00K -1.37B -1.07B -7.0731

Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-10-16 Ripresa H.C. Wainwright Buy
2025-09-10 Ripresa Stifel Buy
2025-09-04 Ripresa Guggenheim Buy
2025-08-05 Reiterato BTIG Research Buy
2025-07-10 Iniziato Goldman Buy
2024-10-24 Iniziato UBS Buy
2024-06-28 Iniziato Jefferies Buy
2024-01-31 Downgrade Scotiabank Sector Outperform → Sector Perform
2023-12-22 Iniziato Mizuho Buy
2023-10-25 Iniziato BofA Securities Buy
2023-10-11 Iniziato Goldman Buy
2023-07-27 Iniziato Scotiabank Sector Outperform
2023-07-11 Iniziato Guggenheim Buy
2023-04-17 Ripresa BTIG Research Buy
2023-01-31 Iniziato Stifel Buy
2023-01-03 Iniziato JP Morgan Overweight
2022-07-28 Ripresa B. Riley Securities Buy
2022-04-11 Iniziato H.C. Wainwright Buy
2022-02-15 Iniziato Goldman Buy
2021-06-04 Ripresa Robert W. Baird Outperform
2021-05-25 Iniziato Citigroup Buy
2021-02-18 Iniziato B. Riley Securities Buy
2020-12-03 Iniziato Stifel Buy
2020-05-22 Aggiornamento Citigroup Neutral → Buy
2020-05-22 Downgrade H.C. Wainwright Buy → Neutral
2020-05-18 Downgrade Citigroup Buy → Neutral
2020-05-11 Reiterato H.C. Wainwright Buy
2020-03-04 Iniziato Barclays Overweight
2020-01-13 Reiterato H.C. Wainwright Buy
2019-03-08 Reiterato H.C. Wainwright Buy
2019-01-04 Iniziato Robert W. Baird Outperform
2018-01-05 Iniziato B. Riley FBR, Inc. Buy
2017-03-16 Iniziato FBR & Co. Outperform
2017-03-02 Iniziato Instinet Buy
2016-10-07 Iniziato Guggenheim Buy
2016-03-28 Iniziato Citigroup Buy
2016-03-28 Iniziato JMP Securities Mkt Outperform
2016-03-28 Iniziato Morgan Stanley Overweight
Mostra tutto

Syndax Pharmaceuticals Inc Borsa (SNDX) Ultime notizie

pulisher
Sep 24, 2026

Diaceutics (DXRX) Enhances Multi-Year Relay Collaboration with Syndax Pharmaceuticals to Advance Acute Leukaemia Precision Oncology Commercialisation - Kalkine Media

Sep 24, 2026
pulisher
Sep 23, 2026

How Syndax Pharmaceuticals Inc. (SNDX) Affects Rotational Strategy Timing - Stock Traders Daily

Sep 23, 2026
pulisher
Sep 22, 2026

H.C. Wainwright Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $38 - Moomoo

Sep 22, 2026
pulisher
Sep 19, 2026

Bank of America Corp DE Purchases New Shares in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat

Sep 19, 2026
pulisher
Sep 18, 2026

Syndax Pharmaceuticals stock holds recent gains as investor conferences and cancer drug outlook draw - AD HOC NEWS

Sep 18, 2026
pulisher
Sep 18, 2026

Syndax Pharmaceuticals, Inc. (SNDX) Stock Analysis: Unveiling a 112% Potential Upside with a Strong Buy Consensus - DirectorsTalk Interviews

Sep 18, 2026
pulisher
Sep 17, 2026

Syndax Pharmaceuticals stock gains on investor conference schedule and steady September trading - AD HOC NEWS

Sep 17, 2026
pulisher
Sep 14, 2026

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Sep 14, 2026
pulisher
Sep 13, 2026

WINTON GROUP Ltd Has $1.67 Million Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat

Sep 13, 2026
pulisher
Sep 13, 2026

How (SNDX) Movements Inform Risk Allocation Models - Stock Traders Daily

Sep 13, 2026
pulisher
Sep 12, 2026

Syndax Pharmaceuticals (SNDX) Stock May Be Pricey Following A 15% Gain - webull.com

Sep 12, 2026
pulisher
Sep 12, 2026

Two talks by Syndax executives will be webcast live from New York in September. - Stock Titan

Sep 12, 2026
pulisher
Sep 11, 2026

Squarepoint Ops LLC Boosts Holdings in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat

Sep 11, 2026
pulisher
Sep 10, 2026

Syndax Pharmaceuticals (NASDAQ:SNDX) Trading Down 6.6%Here's Why - MarketBeat

Sep 10, 2026
pulisher
Sep 10, 2026

Syndax Pharmaceuticals at Citigroup’s Biopharma Back to School Summit 2026: revuforj gains - Investing.com India

Sep 10, 2026
pulisher
Sep 07, 2026

Legal & General Group Plc Takes Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat

Sep 07, 2026
pulisher
Sep 05, 2026

Syndax Pharmaceuticals Stock Price Forecast. Should You Buy SNDX? - StockInvest.us

Sep 05, 2026
pulisher
Sep 04, 2026

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - marketscreener.com

Sep 04, 2026
pulisher
Sep 04, 2026

Nineteen new employees get options to buy up to 175,000 Syndax shares. The options vest over four years. - Stock Titan

Sep 04, 2026
pulisher
Sep 04, 2026

Syndax Pharmaceuticals Inc. (SNDX) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research

Sep 04, 2026
pulisher
Sep 04, 2026

Syndax Pharmaceuticals Inc. (SNDX) Peer Comparison – Compare with Others - Value Research

Sep 04, 2026
pulisher
Sep 04, 2026

Syndax Pharmaceuticals Inc. (SNDX) Key Financial Ratios – Valuation, Profitability & More - Value Research

Sep 04, 2026
pulisher
Sep 04, 2026

Syndax Pharmaceuticals Inc. (SNDX) Financials – Balance Sheet, Profit & Loss, Cash Flow - valueresearchonline.com

Sep 04, 2026
pulisher
Sep 03, 2026

Syndax stock gains attention as investor conferences approach - ad-hoc-news.de

Sep 03, 2026
pulisher
Sep 03, 2026

Pale Fire Capital SE Sells 158,910 Shares of Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat

Sep 03, 2026
pulisher
Sep 02, 2026

(SNDX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily

Sep 02, 2026
pulisher
Sep 02, 2026

Alyeska Investment Group L.P. Acquires Shares of 308,507 Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat

Sep 02, 2026
pulisher
Sep 01, 2026

Syndax Announces Participation in September Investor Conferences - GlobeNewswire

Sep 01, 2026
pulisher
Aug 31, 2026

Man Group plc Takes $4.67 Million Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat

Aug 31, 2026
pulisher
Aug 31, 2026

Bank of New York Mellon Corp Makes New $22.74 Million Investment in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat

Aug 31, 2026
pulisher
Aug 28, 2026

SNDX Q2 2026 Earnings: Wider-than-Expected EPS Loss Triggers Share DeclineEarnings Manipulation Risk - vinanet.vn

Aug 28, 2026
pulisher
Aug 27, 2026

Ieq Capital LLC Takes Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat

Aug 27, 2026
pulisher
Aug 25, 2026

Algert Global LLC Has $22.98 Million Holdings in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat

Aug 25, 2026
pulisher
Aug 25, 2026

Parkman Healthcare Partners LLC Purchases New Shares in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat

Aug 25, 2026
pulisher
Aug 21, 2026

SNDX Maintained by UBS -- Price Target Lowered to $33 - GuruFocus

Aug 21, 2026
pulisher
Aug 21, 2026

UBS lowers Syndax Pharmaceuticals price target on revenue outlook - Investing.com

Aug 21, 2026
pulisher
Aug 21, 2026

UBS lowers Syndax Pharmaceuticals price target on revenue outlook By Investing.com - Investing.com Canada

Aug 21, 2026
pulisher
Aug 21, 2026

UBS Adjusts Price Target on Syndax Pharmaceuticals to $33 From $37, Keeps Buy Rating - finance.yahoo.com

Aug 21, 2026
pulisher
Aug 20, 2026

Syndax (SNDX) Q2 2026 Earnings Call Transcript - AOL.com

Aug 20, 2026
pulisher
Aug 20, 2026

Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates - Eastern Progress

Aug 20, 2026
pulisher
Aug 20, 2026

Syndax (SNDX) Quarterly Results: Profit Per Share Falls Below Its Benchmark in the Reported Period; Trading Move - careplusvn.com

Aug 20, 2026
pulisher
Aug 20, 2026

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat

Aug 20, 2026
pulisher
Aug 20, 2026

Wall Street Analysts Think Syndax (SNDX) Could Surge 70.38%: Read This Before Placing a Bet - Eastern Progress

Aug 20, 2026
pulisher
Aug 19, 2026

Exploring 3 High Growth Tech Stocks In The US Market - Sahm

Aug 19, 2026
pulisher
Aug 18, 2026

Syndax Pharmaceuticals (SNDX) Edges Up 0.46% to $19.85 as Range-Bound Trading PersistsHigh Low Breadth - vinanet.vn

Aug 18, 2026
pulisher
Aug 18, 2026

When Will Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Breakeven? - news.futunn.com

Aug 18, 2026
pulisher
Aug 17, 2026

GSA Capital Partners LLP Purchases New Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat

Aug 17, 2026
pulisher
Aug 14, 2026

Stifel Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $40 - Moomoo

Aug 14, 2026
pulisher
Aug 14, 2026

SNDX Stock Price, Quote & Chart - ChartMill

Aug 14, 2026
pulisher
Aug 12, 2026

The Technical Signals Behind (SNDX) That Institutions Follow - Stock Traders Daily

Aug 12, 2026
pulisher
Aug 12, 2026

Syndax (SNDX) Sales Nearly Doubled, So Why Did The Stock Fall? - Yahoo Finance

Aug 12, 2026

Syndax Pharmaceuticals Inc Azioni (SNDX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$58.29
price up icon 1.11%
$36.13
price down icon 1.87%
$121.55
price up icon 2.71%
$249.59
price up icon 1.25%
ONC ONC
$359.97
price down icon 1.38%
$199.86
price up icon 4.78%
Capitalizzazione:     |  Volume (24 ore):